References

1.

Cohen SB, Emery P, Greenwald MW, et al; for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806. Download Article

2.

Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis. 2010;69(6):1158-1161. Download Article

3.

Data on file, DANCER Trial CSR. Genentech USA, Inc.

4.

Data on file, FDA approval letter, 02/2006. Genentech USA, Inc.

5.

Data on file, FDA approval letter, 04/2011. Genentech USA, Inc.

6.

Data on file, Label update approval letter, 01/2008. Genentech USA, Inc.

7.

Data on file, Label update approval letter, 10/2009. Genentech USA, Inc.

8.

Data on file, REFLEX 2-Year Clinical Study Report. Genentech USA, Inc. and Biogen.

9.

Data on file, REFLEX 6-Month Clinical Study Report. Genentech USA, Inc. and Biogen.

10.

Data on file, REFLEX Trial CSR. Genentech USA, Inc.

11.

Data on file, Rituxan Drug Safety Report, January 2017.

12.

Keystone EC, Cohen SB, Emery P, et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol. 2012;39(12):2238-2246.

13.

Rituxan [package insert]. South San Francisco, CA: Biogen and Genentech USA, Inc.

14.

Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417-427.

15.

van Vollenhoven RF, Emery P, Bingham CO III, et al. Long-term safety of rituximab: 6-year follow-up of the rheumatoid arthritis (RA) clinical trials and re-treatment population. Presented at: American College of Rheumatology Annual Scientific Meeting; October 24-29, 2008; San Francisco, CA. Poster 361.

16.

van Vollenhoven RF, Emery P, Bingham CO III, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical studies. J Rheumatol. 2010;37(3):558-567.

17.

van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of Rituximab: pooled analysis of the rheumatoid arthritis global clinical trial program over 11 years. Presented at: European League Against Rheumatism Conference; June 12-15, 2013; Madrid, Spain. Poster SAT0131.

18.

van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761-1766.